Información del artículo
Resumen
El prolactinoma es el más frecuente de los adenomas secretores de la pituitaria. Es a menudo descubierto entre las mujeres en edad fértil presentando asociación de amenorrea y galactorrea. Datos en la bibliografía de largas series indican los posibles riesgos en la interacción entre prolactinoma y embarazo. Los riesgos han sido sobrevalorados en el pasado. Ahora se sabe que el embarazo puede ser permitido proporcionando un estricto seguimiento con lo que se consigue un éxito asegurado.
Drogas dopaminérgicas no tienen efectos adversos teratogénicos y se sabe que permiten el control del tumor recuperándose la fertilidad en la mayoría de los casos. El uso de esta medicación explica la reducción de la indicación de cirugía.
Los microprolactinomas están altamente influenciados por el embarazo y pueden incluso conducir a la regresión del tumor. Los macroprolactinomas producen complicaciones con mayor frecuencia, y se requiere un buen control del tumor y un riguroso seguimiento.
Summary
Prolactinoma is the most frequent secreting pituitary adenoma and is easy to diagnose in women of childbearing age because of its association with amenorrhea and galactorrhea
Data in the literature from large series indicate current risks of the interaction between prolactinoma and pregnancy. In the past these risks have been overestimated and it is now recognized that pregnancy can be allowed to continue providing it is strictly followed-up
Dopaminergic drugs have no teratogenic effects and, in most cases, are known to allow tumoral control and recovery of fertility. The use of these medications also reduces indications for surgery
Microprolactinomas are relatively unaffected by pregnancy, which can even induce tumor regression. Macroprolactinomas more frequently produce complications and require more aggressive tumor control and rigorous follow-up
El Texto completo está disponible en PDF
Bibliografía
[1.]
I. Tur-Kaspa, I. Paz, N. Gleicher.
Trastornos de la hipófisis y el hipotálamo.
Trata-miento de las complicaciones clínicas del embarazo, 3, pp. 501-511
[2.]
G.N. Burrow, G. Wortzman, N.B. Rewcastle.
Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series.
N Engl J Med, 304 (1981), pp. 156-159
[3.]
G.T. Tindall, D.L. Barrow.
Disorders of the pituitary.
[4.]
M. Molitch.
Evaluation and management of pituitary tumors during pregnancy.
Endocr Practice, 2 (1996), pp. 287-292
[5.]
R.P. Glick, A. Hart.
Diagnóstico y manejo de los tumores encefálicos durante el embarazo.
Tratamiento de las complicaciones clínicas del embarazo, 3, pp. 1500-1518
[6.]
J.S. Sanfilippo, F.M. Akerman.
Lactancia normal y anormal.
Tratamiento de las complicaciones médicas del embarazo, 3, pp. 1561-1568
[7.]
R.E. Blackwell.
Diagnosis and management of prolactino-mas.
Fertil Steril, 43 (1985), pp. 5-9
[8.]
M.L. Vance, M.O. Thorner.
Prolactinomas.
Endocrinol Me-tab Clin North Am, 16 (1987), pp. 731-764
[9.]
M.E. Motlich, E.J. Russell.
The pituitary «incidentaloma».
Am Intern Med, 112 (1990), pp. 925-931
[10.]
BMK Biller, G.H. Daniels.
Regulación endocrina y enfer-medades de la hipófisis anterior y del hipotálamo.
Harrison, 14, pp. 2241-2271
[11.]
R.H. Wilkins.
Enfermedad neoplásica del cerebro.
Medicina clínica en obstetricia, pp. 1234-1242
[12.]
P.R. Garner.
Pituitary disorders in pregnancy.
Curr Obstet Med, 1 (1991), pp. 143-147
[13.]
P.R. Garner.
Trastornos hipofisarios y suprarrenales.
Complicaciones médicas durante el embarazo, 4, pp. 187-208
[14.]
K.J. Zülch.
Brain tumours: their biology and pathology.
2,
[15.]
K. Kovacs, E. Horvath.
Pathology of pituitary tumors.
En-docrinol Metab Clin North Am, 16 (1987), pp. 529-551
[16.]
J. Hardy.
Transphenoidal surgery of hypersecreting pituitary tumours.
Diagnosis and treatment of pituitary tumours, pp. 179-203
[17.]
K. Kovacs, E. Horvath, S.L. Asa.
Classification and pathology of pituitary tumors.
Neurosurgery, pp. 834-842
[18.]
O. Melan.
Neuro-ophtalmologic features of pituitary tumors.
Endocrinol Metab Clin North Am, 16 (1987), pp. 585-607
[19.]
D. Cunnah, M. Besser.
Management of prolactinomas.
Clin Endocrinol (Oxf, 34 (1991), pp. 231-235
[20.]
M.L. Vance, M. Lipper, A. Klibanaski, B.M. Biller, N.A. Samaan, M.E. Molitch.
Treatment of prolactin-secreting pituitary macroadenomas with the longacting non-ergot dopa-mine agonist CV 205-502.
Ann Intern Med, 112 (1990), pp. 668-673
[21.]
C.B. Wilson.
A decade of pituitary microsurgery: the Her-bert olivecrona lecture.
J Neurosurg, 16 (1984), pp. 814-819
[22.]
S. Franks.
Regulation of prolactin secretion by estrogens: physiological and pathological significance.
Clin Sci, 65 (1983), pp. 457-462
[23.]
Adenoma Study Group. Pituitary.
Pituitary adenomas and oral contraceptives: a multicentre case control study.
Fertil Steril, 39 (1983), pp. 753-757
[24.]
L. Speroff, R.H. Glass, N.G. Kase.
Amenorrhea.
Clinical gynecologic en-docrinology and infertility, pp. 165-208
[25.]
J. Schlechte.
The natural history of untreated hyperprolacti-nemia: A prospective analysis.
J Clin Endocrinol Metab, 68 (1989), pp. 412-418
[26.]
JP Jr Holt, M.M. Miller.
Alteraciones del hipotálamo y de la hipófisis en el embarazo.
Medicina clínica en obstetricia, pp. 220-241
[27.]
T. Bergh, S.J. Nillius, L. Wide.
Clinical course and outcome of pregnancies in amenorrheic women with hyperprolacti-nemia and pituitary tumours.
Br Med J, 1 (1978), pp. 875-880
[28.]
C. Gemzell, C.F. Wang.
Outcome of pregnancy in women with pituitary adenoma.
Fertil Steril, 31 (1979), pp. 363-372
[29.]
C.B. Hammond, A.F. Haney, M.R. Land, Merwe JV Van der, S.J. Orly, R.H. Wiebe.
The outcome of pregnancy in patients with treated and untreated prolacting secreting pituitary tumours.
Am J Obstet Gynecol, 147 (1983),
[30.]
T. Berg, S.J. Nillius.
Prolactinomas in pregnancy.
Prolactinomas in pregnancy, pp. 39-44
[31.]
V. Ruiz-Velasco, G. Tolis.
Pregnancy in hyperprolactine-mic women.
Fertil Steril, 41 (1984), pp. 793-805
[32.]
M.E. Molitch.
Pregnancy and the hyperprolactinemic woman.
N Engl J Med, 312 (1985), pp. 1364-1370
[34.]
J. Bringer, I. Monchotte, B. Hedon, P. Mares, B. Giner.
Hy-perprolactinémie et infertilité féminine.
La prolactinee, pp. 191-206
[35.]
P. Fossati, D. Dewailly.
Les stérilités de la femme avec hy-perprolactinémie.
Rev Pract, 33 (1993), pp. 1641-1648
[36.]
C. Helie, H. Mayaudon, B. Bauduceau, J.P. Riveline, M. Ducorps, J.E. Ponties, et al.
Prolactinome et grossesse.
Mise a point à propos de 6 observations, 25 (1996), pp. 174-178
[37.]
F.G. Cunningham, P.C. MacDonald, N.F. Gant, K.J. Leveno, III LC Gilstrap, GDV Hankis, et al.
Enfermedades endocri-nas.
Williams obstetricia, 20, pp. 1137-1150
[38.]
J.P. Raymond, E. Goldstein, P. Konapka, M.F. Leleu, R.E. Merle-ron, Y. Loria.
Follow-up children born of bromocripti-ne treated mothers.
Horm Res, 22 (1985), pp. 239-246
[39.]
T. Bergh, S.J. Nillius, P. Enoksson.
Bromocriptine induced preguancies in women with large prolactinomas.
Clin En-docrinol, 5 (1986), pp. 325-331
[40.]
J.E. Tyson, P. Hwang, H. Guyda, H. Friesen.
Studies of pro-lactin secretion in human pregnancy.
Am J Obstet Gynecol, 113 (1972), pp. 14-19
[42.]
R.A. Maurer.
Relationship between estradiol, ergocryptine, and thyroid hormone: effects of prolactin synthesis and prolactin messenger ribonucleic acid levels.
Endocrino-logy, 110 (1982), pp. 1515-1521
[43.]
A.C. Dalkin, J.C. Marshall.
Medical therapy of hyperprolac-tinemia.
Endocrinol Metab Clin North Am, 18 (1989), pp. 259-284
[45.]
C. Gemzell.
Induction of ovulation in infertile women with pituitary tumors.
Am J Obstet Gynecol, 121 (1975), pp. 311-315
[46.]
R. Jewelewicz, E.A. Zimmerman, P.W. Carmel.
Conservative management of a pituitary tumor during pregnancy following induction of ovulation with gonadotropins.
Fertil Steril, 28 (1977), pp. 35-40
[47.]
A. Loucopoulos, R. Jewelewicz.
Prolactinomas and pregnancy.
Seminars in reproductive endocrinology (Vol 2, pp. 83-88
[48.]
R. Jewelewicz.
Therapeutic use of bromocriptine in women with amenorrhea-galactorrhea and suspected pituitary mi-croadenoma.
Ergot compounds and brain function: neuroendo-crine and neuropsychiatric aspects, pp. 209-225
[49.]
R. Jewelewick, Wiele RH. Vande.
Clinical course and outcome of pregnancy in twenty-five patients with pituitary microadenomas.
Am J Obstet Gynecol, 136 (1980), pp. 339-343
[50.]
A.M. Landoldt, P.J. Keller, E.R. Froesch.
Bromocriptine: does it jeopandise the result of later surgery for prolactinomas?.
Lancet, 2 (1982), pp. 657-658
[51.]
M.E. Molitch.
Management of prolactinomas.
Annu Rev Med, 40 (1989), pp. 225-232
[52.]
O. Serri, E. Rasio, H. Beauregard, J. Hardy, M. Somma.
Recurrence of hyperprolactinemia alter selective trans-sphenoidal adenomectomy in women with prolactinoma.
N Engl J Med, 309 (1983), pp. 280-283
[53.]
N.T. Zervas.
Surgical results for pituitary adenomas: results of an international survey.
Secretory tumouts of the pituitary gland, pp. 377-385
[54.]
P. Fossatti, D. Dewailly, J. Buvat.
Les troubles de la fertilité d’origine endocrinienne.
Encycl Med Chir Glandes-Nutrition,
[55.]
M.E. Molitch, R.L. Elton, R.E. Blackwell, B. Caldwell, R.J. Chang, R. Jaffe, et al.
Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicentre study.
J Clin Endocrinol Metab, 60 (1985), pp. 698-705
[56.]
G.E. Sheline, A. Grossman, A.E. Jones.
Reaction theraphy for prolactinomas.
Secretory tumours of the pituitary gland, pp. 93-108
[57.]
S.L. Tan, H.S. Jacobs.
Management of prolactinomas.
Br J Obstet Gynaecol, 93 (1986), pp. 1025-1029
[58.]
B.H. Albrecht, G. Betz.
Prolactin-secreting pituitary tumors and pregnancy.
Contemporary issues in endocrinology and metabolism: prolactinomas (Vol VII, pp. 195-217
[59.]
J.E. Barnes, K.H. Abbott.
Cerebral complications incurred during pregnancy and the puerperium.
Am J Obstet Gyne-col, 82 (1961), pp. 192-197
[60.]
HBR Dommerholt, J. Assies, Werf AJM. Van der.
Growth of a prolactinoma during pregnancy.
Br J Obstet Gynaecol, 88 (1981), pp. 62-67
[61.]
R.D. Kempers, R.H. Miller.
Management of pregnancy associated with brain tumors.
Am J Obstet Gynecol, 87 (1963), pp. 858-863
[62.]
P.R. Garner.
Pituitary and adrenal disorders in pregnancy.
Medicine, 35 (1986), pp. 5592-5597
[63.]
B. Corenblum.
Successful outcome of ergocriptine-induced pregnancies in twenty-one women with prolactin-secreting pituitary adenomas.
Fertil Steril, 32 (1979), pp. 183-186
[64.]
T. Bergh, S.J. Nillius, S.G. Larsson.
Effects of bromocriptine-induced pregnancy on prolacting-secreting pituitary tumors.
Acta Endocrinol (Kbh, 98 (1981), pp. 333-338
[65.]
M.J. Kupersmith, C. Rosenberg, D. Kleinberg.
Visual loos pregnant women with pituitary adenomas.
Ann Intern Med, 121 (1994), pp. 473-478
[66.]
P.B. Nelson, A.G. Robinson, D.F. Archer.
Symptomatic pituitary tumor enlargment after induced pregnancy.
Obstet Gynecol Surv, 34 (1974), pp. 206-208
[67.]
P.J. Derome, A. Visot, O. Delalande, C.P. Jedinak, M. Dupuis.
Traitment chirurgical des adénomes à prolactine.
La prolactine, pp. 167-174
[68.]
P. Konopka, J.P. Raymond, R.E. Merceron, J. Seneze.
Continuous administration of bromocriptine in the prevention of neurogical complications in pregnant women with prolactinomas.
Am J Obstet Gynecol, 146 (1983), pp. 935-938
[69.]
R. Marnex, J. Orgiazzi, B. Hughes.
Normal pregnancies after treatment of hyperprolactinemia with bromoergocripti-ne, despite suspected pituitary tumors.
J Endocrinol Metab, 47 (1978), pp. 290-295
[70.]
M.M. Esri, J.S. Bevan, C.W. Burke, CBT. Adams.
Effect of bromocriptine treatment on the fibrous tissue content on prolactin-secreatin and non functionning macroadenomas of the pituitary gland.
J Clin Endocrinol Metab, 63 (1986), pp. 383-388
[71.]
P. Fossati, C. Lamaire, C. Cortet, D. Dewailly, A. Lemaire, C. Fermon, et al.
Prolactinomas et grossesse.
Rev Fr Endo-crinol Clin, 35 (1994), pp. 15-30
[72.]
U. Holmgrem, G. Bergstrand, K. Hagenfeld, S. Werner.
Women with prolactinoma effect of pregnancy and lactation on serum prolactin and on tumor growth.
Acta Endocrinol, 111 (1986), pp. 452-459
[73.]
W. De Wit, HJT. Gerards JL. Coelingh-Bennink.
Prophy-lactic bromocriptine treatment during pregnancy in women with macroprolactinomas: Report of 13 pregnancies.
Br J Obstet Gynaecol, 91 (1984), pp. 1059-1069
[74.]
E. Van Roon, Vijver J Van der, G. Gerretsen.
Rapid regression of a suprasellar extending prolactinoma after bromo-criptine treatment during pregnancy.
Fertil Steril, 36 (1982), pp. 173-177
[75.]
T. Maeda, T. Ushiroyama, F. Okuda, A. Fujimoto, M. Ueki, O. Sugihoro.
Effective bromocriptine treatment of a pituitary macroadenoma during pregnancy.
Obstet Gynecol, 61 (1983), pp. 117-121
[76.]
P.A. O’Donovan, P.L. O’Donovan, E.H. Richie.
Apoplexy into a prolactin secreting macroadenoma.
Br J Obstet Gy-naecol, 93 (1986), pp. 389-395
[77.]
SWJ Lamberts, J.G. Klijn, S.A. De Lange.
Incidence of complications during pregnancy after treatment of hyperpro-lactinemia with bromocriptine in patients with radiologically evident pituitary tumors.
Fertil Steril, 31 (1979), pp. 614-619
[78.]
T. Hirohita, T. Mazomi, K. Mukada, K. Arita, K. Kurisu, T. Yano, et al.
Influence of pregnancy on the serum prolactin level following prolactinoma surgery.
Acta Endocrinol, 125 (1991), pp. 259-267
[79.]
S. Nadalon, De Buhan, F. Archambeaud-Mouveroux, M.P. Four-nier, M.C. Huc, B. Laubie.
Traitment des adénomes à prolactine.
Rev Med Intern, 11 (1990), pp. 172-180
[80.]
C. Lemaire, D. Dewailly, P. Fossati.
Devenir à long terme chez la femme des hyperprolactinémies (micro-adénomes et idiopathiques) traités par les agonistes dopaminergiques.
Rev Fr Endocrinol Clin Nutr Metab, 30 (1989), pp. 346-347
[81.]
Y. Lorcy.
Hyperprolactinémie et grossesse.
Cycleos, 6 (1990), pp. 1-4
[82.]
I. Miyai, K. Ichihara, K. Kondo, S. Mori.
Asymptomatic hyperprolactinemia in the general population-mass screening by paired assays of serum prolactin.
Clin Endocrinol (Oxf, 25 (1986), pp. 549-554
[83.]
M.C. Powell, B.S. Worthington, J.M. Buckley, E.M. Symonds.
Magnetic resonance imaging (MRI) in obstetrics.
I. Maternal anatomy. Br J Obstet Gynaecol, 95 (1988), pp. 38-46
[84.]
R. Kanal.
An overview of electromagnetic safety considerations associated with magnetic resonance imaging.
Ann NY Acad Sci, 649 (1992), pp. 204-224
[85.]
A.L. Stein, M.N. Levenick, O.A. Kletzky.
Computed tomography versusresonance magnetic imaging for the evaluation of suspected pituitary adenomas.
Obstet Gynecol, 73 (1989), pp. 996-999
[86.]
M.O. Thorner, CRW Edwards, M. Charlesworth, J.E. Dacie, P.J. Moult, L.H. Rees, et al.
Pregnancy in patients presenting with hyperprolactinemia.
Br Med J, 2 (1979), pp. 771-774
[87.]
J.O. Donaldson.
Complicaciones neurológicas.
Complicaciones médicas durante el embarazo, 4, pp. 482-498
[88.]
K.A. Burry, H.S. Schiller, R. Mills.
Acute visual loss during pregnancy alter bromocriptine induced ovulation.
Obstet Gynecol, (1978;v52), pp. 195-225
[89.]
R.W. Griffith, I. Turkal, P. Braun.
Pituitary tumors during pregnancy in mother treated with bromocriptine.
Br J Clin Pharmaco, 7 (1979), pp. 393-396
[90.]
R.H. Simon.
Brain tumors in pregnancy.
Semin Neurol, 8 (1988), pp. 214-220
[91.]
C.H. Hammond, A.F. Haney, M.R. Land.
The outcome of pregnancy in patients wits with treated and untreated pro-lactin-secreting pituitary tumors.
Am J Obstet Gynecol, 147 (1983), pp. 148-152
[92.]
N.A. Samaan, P.N. Schultz, T.A. Leavens.
Pregnancy after treatment in patients with prolactinoma: operations versusbromocriptine.
Am J Obstet Gynecol, 155 (1986), pp. 1300-1306
[93.]
P. Krupp, I. Turkalj.
Surveillance of bromocriptine in pregnancy and offspring.
Pro-lactinomas in pregnancy, pp. 45-50
[94.]
P. Krupp, C. Monka, K. Ritcher.
The safety aspects of infertility treatments [resumen].
Río de Janeiro, Second World Congress of Gynecology and Obstetrics, pp. 9
[95.]
E.E. Wilson, B.B. Little.
Endocrine disorders during pregnancy: embryotoxic versus fetal effects.
Drungs and pregnancy, pp. 209-245
[96.]
D. Prager, G.D. Braunstein.
Pituitary disorders during pregnancy.
Endocrinol Metab Clin North Am, 24 (1995), pp. 1-4
[97.]
E. Del Pozo, A. Darragh, I. Lancranjan.
Effect of bromocrip-tine on the endocrine system and fetal development.
Clin Endocrinol, 6 (1977), pp. 475-480
[98.]
P. Krupp, C. Monka.
Bromocriptine in pregnancy: safetty aspects.
Klin Wochenschr, 65 (1987), pp. 823-827
[99.]
M. Bigazzi, R. Lancranjan I. Ronga.
A pregnancy in an acromegalic woman during bromocriptine treatment: effects on growth hormone and prolactin in the maternal, fetal, and amniotic compartments.
J Clin Endocrinol Metab, 48 (1979), pp. 9-14
[100.]
I. Turkalj, P. Braun, P. Krupp.
Surveillance of bromocriptine in pregnancy.
JAMA, 247 (1982), pp. 1589-1594
[101.]
O. Ylirkorkala, S. Kivihen, L. Ronnberg.
Bromocriptine treatment during early human pregnancy: effect on the levels of prolactin, sex steroids and placental lactogen.
Acta En-docrinol, 95 (1980), pp. 412-417
[102.]
H. Scherrer, G. Turpin, Y. Darbois, J. Metzger, J.L. De Gennes.
Grossesses et hyperprolactinémie. Révision des moda-lités thérapeutiques à propos d’une série de 35 patients.
Ann Med Intern, 137 (1986), pp. 621-626
[103.]
J. Brotchi, J. Barrat, C. Faguer.
Pathologie neuro-chirurgica-le.
Traité d’obstetrique (III, pp. 147-151
[104.]
L. Speroff, R.H. Glass, N.G. Kase.
The breast.
Clinical gynecologic endo-crinology and infertility, pp. 547-592
[105.]
J.M. Barguno, E. De Pozo, M. Cruz, J. Figueras.
Failure of maintained hyperprolactinemia to improve lactational perforance in later puerperium.
J Clin Endocrinol Metab, 66 (1988), pp. 876-881
[106.]
B.H. Yuen.
Prolactin in human milk: the influence of nursing and the duration of postpartum lactation.
Am J Obstet Gynecol, 136 (1980), pp. 980-985
[107.]
A. Zarate, E.S. Canales, M. Alger.
The effect of pregnancy and lactation on pituitary prolactin-secreting tumors.
Acta Endocrinol (Kbh, 92 (1979), pp. 407-412
[108.]
López LC Tejerizo, Sesmero JR De Miguel, Esca-nilla JA Pérez, Moro F. Corredera.
Implicaciones de las enfer-medades maternas en la lactancia natural.
Manual de asistencia al parto y puer-perio patológicos, pp. 831-869
[109.]
J. Buvat, M. Buvat-Herbaut.
Prolactine, bromocriptine et fonction gonadique de la femme: données récents.
J Gyne-col Obstet Biol Reprod, 11 (1982), pp. 509-521
[110.]
R. Mornex, B. Hugues.
Hyperprolactinémie et grossesse.
Rev Fr Endocrinol Clin, 30 (1989), pp. 339-343
[111.]
T. Bergh, S.J. Nillius.
Prolactinomas: follow-up of medical treatment.
A clinical Problem: microprolactinoma, pp. 115-130
[112.]
T.C. Vaughn, A.F. Haney, R.H. Wiebe.
Spontaneous regression of prolactin-producing pituitary adenomas.
Am J Obs-tet Gynecol, 136 (1980), pp. 980-984
[113.]
T.L. Martin, M. Kim, W.B. Malarkey.
The natural history of idiopathic hyperprolactinemia.
J Clin Endocrinol Metab, 60 (1985), pp. 855-860
[114.]
R. Comtois, S. Bertrand, H. Beairegard.
Spontaneaus regression of a prolactin-producing pituitary adenoma during pregnancy.
Am J Med, 83 (1987), pp. 1005-1010
[115.]
C. Rasmussen, T. Bergh, L. Wide.
Prolactin secretion and menstrual function after long-term bromocriptine treatment.
Fertil Steril, 48 (1987), pp. 550-556
[116.]
M.C. Pereira, L.G. Sobrinho, A.M. Alfonso.
Is idiopathic hy-perprolactinemia a transitional stage toward prolactinoma?.
Obstet Gynecol, 70 (1987), pp. 305-311
[117.]
D.F. Archer.
Current concepts and treatment of hyperpro-lactinemia.
Obstet Gynecol Clin North Am, 14 (1987), pp. 979-1003
[118.]
W.B. Malarkey, R. Jackson, J. Wortsman.
Long-term assessment of patients with macroprolactinemia.
Fertil Steril, 50 (1988), pp. 413-419
[119.]
C. Bricaire, V. Kerlan, F. Kutten, P. Mauvais-Jarvis.
La gros-sesse: une modalité de guérison des adénomes à prolacti-ne?.
Presse Med, 17 (1988), pp. 2117-2119
[120.]
S. Daya, A. Schewchuck, N. Bryceland.
The effect of multiparity on intrasellar prolactinomas.
Am J Obstet Gynecol, 148 (1984), pp. 512-515
[121.]
J. Schlechte, B. Sherman.
Hyperprolactinemia and osteoporosis.
Seminars in reproductive endocrinology (Vol 2, pp. 89-92
[122.]
H.A. Zacur.
Oral contraceptive pills and prolactin. Seminars in reproductive.
Endocrinology, 7 (1989), pp. 239-245
[123.]
J. Blankstein, S. Mashiach, B. Lunenfeld.
Prolactin-inhibiting agents.
Ovulation induction and in vitrofertilization, pp. 77-104
[124.]
C. Ferrari, C. Barbieri, R. Caldara, M. Mucci, F. Codecasa, A. Paracchi, et al.
Long-lasting in hyperprolactinemia patients.
J Clin Endocrinol Metab, 63 (1986), pp. 941-945
[125.]
G.B. Mattei, C. Ferrari, P. Baroldi, V. Cavioni, A. Paracchi, C. Galparoli, et al.
Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemia patients.
J Clin Endocrinol Metab, 66 (1988), pp. 193-198
[126.]
C. Ferrari, A. Mattei, G.B. Melis, A. Paracchi, M. Muratori, G. Faglia, et al.
Cabergoline: long-anting oral treatment of hyperprolactinemia disorders.
J Clin Endocrinol Metab, 68 (1989), pp. 1201-1206
[127.]
Multicentre Study Group for Cabergoline in Lactation Inhibition. European.
Single dose cabergoline versusbro-mocriptine in inhibition of puerperal lactation: randomi-sed, double-blind multicentre study.
Br Med J, 302 (1991), pp. 1367-1371
[128.]
J. Webster, G. Piscitelli, A. Polli, A. D-Alberton, L. Falsetti, C. Ferrari, et al.
Dose-dependent suppression of serum pro-lactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study.
Clin Endocri-nol, 37 (1992), pp. 524-541
[129.]
J. Webster, G. Piscitelli, A. Polli, A. D-Alberton, L. Falsetti, C. Ferrari, et al.
The efficacy and tolerability of cabergoli-ne therapy in hyperprolactinemia disorder: an open, un controlled multicentre study.
Clin Endocrinol, 39 (1993), pp. 323-329
[130.]
J. Webster, G. Piscitelli, A. Polli, C. Ferrari, I. Ismail, M.F. Scan-lon.
A comparison of cabergoline and bromocriptine in the treatment of hyper prolactinemia amenorrhea.
N Engl J Med, 331 (1994), pp. 904-909
[131.]
J. Webster.
A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprotacti-naemia and inhibition of lactation.
Drug Safety, 14 (1996), pp. 228-238
[132.]
NRC Musolino, Neto MB Cunha, R. Marino, M.D. Bronstein.
Cabergoline in the management of prolactinoma patients with intolerance and for resistance to bromocriptine (resumen). San Diego.
pp. 114
[133.]
Pharmacia and Upjohn.
Dostinex (cabergolinum) dopami-ne agonista, prolactin inhibitor.
Arzneimittel-Kompendium der Schweiz, pp. 633-634
[134.]
W.J. Jeffcoate, N. Pound, NCD Sturrock, J. atLongterm follow-up of patients with hyperprolactinemia. Lambourne.
Clin Endocrinol (Oxf, 45 (1996), pp. 299-303
[135.]
BMK Biller, M.E. Molitch, M.L. Vance, K.B. Cannistraro, K.R. Da-vis, J.A. Simons, et al.
Treatment of prolactin-secreting macroadenoma with oncea week dopamine agonist caber-goline.
J Clin Endocrinol Metab, 81 (1996), pp. 2338-2343
[136.]
M.E. Molitch, M.O. Thorner, C. Wilson.
Management of pro-lactinomas.
J Clin Endocrinol Metab, 82 (1997), pp. 996-1000
[137.]
A. Colao, Sarno A Di, M.L. Landi, S. Cirillo, F. Sarnacchiaro, G. Facciolli, et al.
Long-term and low dose treatment with cabergoline induces macroprolactinoma shrinkage.
J Clin Endocrinol Metab, 82 (1997), pp. 3574-3579
[138.]
A. Colao, S. Loche, M. Cappa, Sarno A Di, M.L. Landi, F. Sar-nacchiano, et al.
Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.
J Clin Endocrinol Metab, 83 (1998), pp. 2777-2780
[139.]
J. Verhelst, C. Mahler, R. Abs, M. De Longueville.
Preliminary results with a new non ergot derived dopamine agonist in the treatment of prolactinomas.
J Endocr Invest, 13: (1990), pp. 140
[140.]
R. Homburg, Z. Shoham, H.S. Jacobs.
Clinical aspects of female hyperprolactinemia: treatment with CV 205-502 compared with bromocriptine.
Progress in prolactin-lowering therapy, pp. 19-35
[141.]
P.S. Barnett, P. Coskeran, J. Butler, J.M. Dawson, J.J. Maccabe, Gregor AM. Mc.
The role of CV 205-502 in the management of patients with prolactin-secreting pituitary ma-croadenomas.
Progress in prolactin-lowering therapy, pp. 37-44
[142.]
L. Duranteau, P. Chanson, A. Lavoinne, S. Horlait, J. Lubetzki, J.M. Kuhn.
Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bro-mocriptine-resistant prolactinomas.
Clin Endocrinol, 34 (1991), pp. 25-29
[143.]
Z. Shoham, R. Homburg, H.S. Jacobs.
CV 205-502 effectiveness, tolerability, and safety over 24- month study.
Fertil Steril, 55 (1991), pp. 501-506
[144.]
F. Pieter, Heijden M Van der, W. De Uit, J. Brownell, J. Scho-emaker, R. Rolland.
CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolac-tinaemia.
Eur J Obstet Gynecol Reprod Biol, 40 (1991), pp. 111-118
[145.]
M.J. Abrahamson, L. Handler, M. Isaacs.
Effects of CV 205-502 on growth hormone and prolactin secretion in acromegaly and hyperprolactianemic states including micro and ma-croprolactinomas.
J Endocr Invest, 14 (1991), pp. 105
[146.]
A. Beckers, A.E. Ghuysen, R. Abs, J. Verhelst, M. De Longuevi-lle, C. Mahler, et al.
Le traitement des prolactinomes par un nouvel agoniste dopaminergique (CV 205-502.
résul-tats chez 48 patients. Med Hyg, 50 (1992), pp. 2064-2067
[147.]
R. Razzaq, D.J. O’Halloram, C.G. Beardwell, S.M. Shalet.
The effects of CV 205-502 in patients with hyperprolactinae-mia intolerant and for resistant to bromocriptine.
Horm Res, 39 (1993), pp. 218-222
[148.]
Salmón G Fanghanel, Reyes L Sánchez, E. Valdés, Hoza JL Salga-do, Campos J. Espinoza.
Eficacia, tolerabilidad y seguridad de la quinagolida en pacientes con hiperprolacti-nemia tumoral.
Invest Med Int, 22 (1995), pp. 30-35
[149.]
E. Kousta, D.M. White, S. Franks, D.G. Johnston.
Use of qui-nagolide in hyperprolactinaemia patients who are intolerant and for resistant to bromocriptine.
J Endocrinol, 114 (1995), pp. 158
[150.]
L. Morange, A. Barbier, T. Brue, P. Jaquet.
Efficacité a long terme du quinagolide dans les prolactinomes resistants a la bromocriptine.
Ann Endocrinol, 57 (1996), pp. 337
[151.]
L. Morange, A. Barlier, I. Pellegrini, Bruet, A. Enjalbert, P. Ja-quet.
Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.
Eur J Endocrinol, 135 (1996), pp. 413-420
[152.]
J.M. Tremble, P.S. Barnet, Gregor AM. Mc.
Norprolac® in the management of macroprolactinomas.
Norprolac® (quinagolide, pp. 12-15
[153.]
J. Brownell, C. Monka, P. Ksapp.
Norprolac® in pregnancy.
Norporlac® (quinagolide, pp. 26-28
[154.]
J. Brownell.
Quinagolide (Norprolac®): a novel non-ergot prolactin inhibition.
Drugs Today, 32 (1996), pp. 77-104
[155.]
J. Brownell.
Quinagolide in hyperprolactinaemia.
Rev Con-temp Pharmacother, 9 (1998), pp. 1-75
[156.]
E. Robert, L. Musatti, G. Pisticelli.
Pregnancy outcome after treatment with the ergot derivate cabergoline.
Reprod To-xicol, 10 (1996), pp. 333-337
[157.]
F.R. Pérez-López.
Hiperprolactinemia y antiprolactínicos.
Hormonas y antihormonas en Ginecología, (1998), pp. 135-149
[158.]
J. Brownell.
Quinagolide.
Drugs Today, 32 (1996), pp. 1-32
[159.]
Roura A. Cabero.
Hiperprolactinemia. Prolactinoma. Proto-colos de la Sociedad Española de Ginecología y Obstetri-cia.
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
